Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast cancer.
We undertook a preliminary study to examine the response rate of recombinant interleukin-2 (rIL-2) in patients with advanced measurable breast cancer, in a phase II clinical trial. The regimen we utilized was designed to allow outpatient administration. A treatment cycle consisted of low-dose cyclophosphamide (350 mg/m2) given on day -3 followed by the bolus administration of rIL-2 (3.6 x 10(6) Cetus units/m2) on days 1-5, and 8-12. Toxicity was significant but acceptable. One partial remission was seen in 13 evaluable patients. In 2 additional patients clear evidence of an antitumor response was observed. The study was terminated prematurely owing to a shortage of rIL-2. Additional evaluation of rIL-2 in breast cancer appears warranted.
Spicer
D V
DV
Department of Medicine, University of Southern California School of Medicine, Los Angeles.
Kelley
A
A
Herman
R
R
Dean
G
G
Stevenson
L
L
Mitchell
M S
MS
D000328:Adult; D001943:Breast Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000628:therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use*; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects
D007376:Interleukin-2; D011994:Recombinant Proteins; D003520:Cyclophosphamide